ESTRO 2025 - Abstract Book

S1288

Clinical - Lung

ESTRO 2025

Kaplan Meir (KM) analysis showed development of DIP reduced 3-year LC and PFS; LC 53% vs. 75.5% (HR 2.15, p=0.031); PFS 35.5% vs. 56.5% (HR 1.8, p=0.04) and only trended towards reduced OS; (66% vs. 77.5% HR 1.5, p=0.27) (fig 2).

Conclusion: The risk of developing DIP correlated on UVA with advanced tumor stage, adaptive replanning and dosimetric parameters: total lung V20 ≥27%, ipsilateral lung V5 ≥71%, MLD ≥16 Gy, heart V40 ≥4% and MHD ≥6Gy. MVA showed higher DIP risk for ipsilateral lung V5 ≥70% (all grades) and lungs V20 ≥27% (grades G2-5 DIP). KM analysis showed developing DIP reduced LC and PFS and trended towards reduced OS.

Keywords: pneumonitis, durvalumab, PACIFIC regimen